Marilyne Labrie

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

Jianfeng Shen, Wei Zhao, Zhenlin Ju et al. · Cancer Research · 2018 · 561 citations · Full text

A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer

Xinxin Peng, Xiaoyan Xu, Yumeng Wang et al. · Cancer Cell · 2018 · 242 citations · Full text

Proteomic Diversity, Rna Biology, Gene Expression +3

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

Yong Fang, Daniel J. McGrail, Chaoyang Sun et al. · Cancer Cell · 2019 · 231 citations · Full text

Clinical Therapeutic, Medicine, Pharmacotherapy +4

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton et al. · Clinical Cancer Research · 2021 · 71 citations · Full text

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Beike Wang, Wei Zhang, Gao Zhang et al. · Oncogene · 2021 · 56 citations · Full text